Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma.
作者信息
Lee Ji Yeon, Sung Pil Soo
机构信息
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea.
出版信息
Gut Liver. 2024 Jul 15;18(4):558-559. doi: 10.5009/gnl240274.
Abstract
摘要
相似文献
1
Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma.临床参数作为肝细胞癌中阿替利珠单抗和贝伐单抗治疗的预测因素效果良好。
Gut Liver. 2024 Jul 15;18(4):558-559. doi: 10.5009/gnl240274.
2
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.分析预测阿替利珠单抗和贝伐珠单抗治疗晚期肝细胞癌患者真实世界疗效的因素。
Gut Liver. 2024 Jul 15;18(4):709-718. doi: 10.5009/gnl240085. Epub 2024 Jun 27.
3
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
4
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.阿替利珠单抗治疗晚期肝细胞癌：好事多磨。
Immunotherapy. 2021 Jun;13(8):637-644. doi: 10.2217/imt-2021-0026. Epub 2021 Apr 6.
5
Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.考虑营养状况以改善接受阿替利珠单抗-贝伐单抗治疗的晚期肝细胞癌患者的预后。
Liver Int. 2024 Jun;44(6):1276-1277. doi: 10.1111/liv.15887.
6
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
7
Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab.使用阿替利珠单抗联合贝伐单抗治疗肝细胞癌时向转化治疗转变的预测因素。
Liver Int. 2024 Jul;44(7):1735. doi: 10.1111/liv.15944. Epub 2024 May 8.
8
Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report.阿特珠单抗和贝伐单抗治疗肝细胞癌后经导管动脉栓塞术的三例有效病例：病例报告
J Med Case Rep. 2025 Jan 27;19(1):38. doi: 10.1186/s13256-025-05040-5.
9
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.阿替利珠单抗联合贝伐单抗治疗肝细胞癌时影像学表现与生化反应差异的临床意义
Clin Mol Hepatol. 2022 Jul;28(3):575-579. doi: 10.3350/cmh.2022.0047. Epub 2022 Apr 21.
10
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益分析
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
本文引用的文献
1
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.分析预测阿替利珠单抗和贝伐珠单抗治疗晚期肝细胞癌患者真实世界疗效的因素。
Gut Liver. 2024 Jul 15;18(4):709-718. doi: 10.5009/gnl240085. Epub 2024 Jun 27.
2
Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC.肝内 IgA 复合物诱导 HCC 肿瘤微环境中的癌相关成纤维细胞向基质表型极化。
Hepatology. 2024 Nov 1;80(5):1074-1086. doi: 10.1097/HEP.0000000000000772. Epub 2024 Feb 15.
3
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.系统治疗下循环肿瘤 DNA 超低频全基因组测序对肝细胞癌的预后价值。
Clin Mol Hepatol. 2024 Apr;30(2):177-190. doi: 10.3350/cmh.2023.0426. Epub 2023 Dec 29.
4
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.预测阿特珠单抗和贝伐珠单抗治疗肝细胞癌患者的结局。
Int J Mol Sci. 2023 Jul 22;24(14):11799. doi: 10.3390/ijms241411799.
5
Radiologic features of hepatocellular carcinoma related to prognosis.肝细胞癌的放射学特征与预后的关系
J Liver Cancer. 2023 Mar;23(1):143-156. doi: 10.17998/jlc.2023.02.16. Epub 2023 Mar 9.
6
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison.亚洲肝细胞癌管理临床实践指南概述：亚洲视角比较。
Clin Mol Hepatol. 2023 Apr;29(2):252-262. doi: 10.3350/cmh.2023.0099. Epub 2023 Mar 10.
7
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.联合检测 PIVKA-II 和 AFP 在亚太地区肝细胞癌监测和随访中的应用。
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.
8
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
9
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
10
The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.基于全身炎症反应的格拉斯哥预后评分：癌症患者十年的经验。
Cancer Treat Rev. 2013 Aug;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003. Epub 2012 Sep 17.
Zotero 插件